- Home
- ALZN
ALZN
Alzamend Neuro Inc.
as of 12-10-2025 3:44pm EST
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 9.0M | IPO Year: | 2021 |
| Target Price: | $42.00 | AVG Volume (30 days): | 97.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.88 - $12.06 | Next Earning Date: | 12-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ALZN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alzamend Neuro Inc. (ALZN)
Director
Avg Cost/Share
$2.29
Shares
30
Total Value
$68.70
Owned After
25
SEC Form 4
Director
Avg Cost/Share
$2.49
Shares
57,379
Total Value
$142,954.04
Owned After
68,848
SEC Form 4
Director
Avg Cost/Share
$2.45
Shares
82,033
Total Value
$201,267.97
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.33
Shares
3,566
Total Value
$8,320.90
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.31
Shares
38,324
Total Value
$88,490.12
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.31
Shares
37,738
Total Value
$87,344.60
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.31
Shares
14,628
Total Value
$33,828.71
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.31
Shares
39,140
Total Value
$90,374.26
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.38
Shares
43,238
Total Value
$102,720.52
Owned After
68,848
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.35
Shares
77,009
Total Value
$180,855.64
Owned After
68,848
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McGrath Lynne Fahey | ALZN | Director | Oct 23, 2025 | Sell | $2.29 | 30 | $68.70 | 25 | |
| AULT MILTON C III | ALZN | Director | Oct 7, 2025 | Sell | $2.49 | 57,379 | $142,954.04 | 68,848 | |
| AULT MILTON C III | ALZN | Director | Oct 6, 2025 | Sell | $2.45 | 82,033 | $201,267.97 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 30, 2025 | Sell | $2.33 | 3,566 | $8,320.90 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 29, 2025 | Sell | $2.31 | 38,324 | $88,490.12 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 26, 2025 | Sell | $2.31 | 37,738 | $87,344.60 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 25, 2025 | Sell | $2.31 | 14,628 | $33,828.71 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 24, 2025 | Sell | $2.31 | 39,140 | $90,374.26 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 23, 2025 | Sell | $2.38 | 43,238 | $102,720.52 | 68,848 | |
| AULT MILTON C III | ALZN | Director, 10% Owner | Sep 19, 2025 | Sell | $2.35 | 77,009 | $180,855.64 | 68,848 |
Compare ALZN vs Leading Stocks
See how ALZN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALZN Alzamend Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.